You are here
Publications
Popular Publications
COVID-19 Response - Costing and pricing guidelines
17 August 2020This document guides costing practitioners on the steps to capturing end-to-end COVID-19 activity and expenses under the National Partnership Agreement (NPA). It identifies the principles to be applied, the scope of activity and costs to be funded, cost allocation methods and NPA specific cost centres for cost allocation. This document also introduces two new non-patient products and provides information on how to create and map intermediate products.
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding
18 June 2020The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
Three Year Data Plan 2020–21 to 2022–23
4 June 2020IHPA requires accurate activity, cost and expenditure data from jurisdictions on a timely basis in order to perform its core determinative functions. This data plan sets out IHPA's eighth rolling Three Year Data Plan, covering the period 2020–21 to 2022–23. The Three Year Data Plan specifies the data requirements and timelines that IHPA will use to collect data over the next three years.
Rules for coding and reporting COVID-19 episodes of care
1 May 2020On 13 March 2020, the Commonwealth and all state and territory governments signed the National Partnership on COVID-19 Response, in order to provide financial assistance for the additional costs incurred by health services in responding to the coronavirus disease 2019 (COVID-19) outbreak.